Ipsos Healthcare has launched its syndicated Multiple Sclerosis (MS) Patient Community Panel, comprising patients across the EU5 and US with a mix of treatment experiences.
The new panel is part of the Ipsos Healthcare Global Patient Centre of Excellence and will run alongside the firm's existing MS Therapy Monitor. Patients will take part in a range of tasks throughout the year (both syndicated and proprietary), all moderated by Ipsos Healthcare's MS experts, enabling subscribers to explore key topics while tapping into the community to answer business questions as they arise.
Paul O'Meara (pictured), Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare, comments: 'As patients move from recipients to participants, there is an imperative for pharma to put them at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalised medicine strategies for those living with MS'.
Web site: www.ipsos.com .
All articles 2006-19 written and edited by Mel Crowther and/or Nick Thomas.